By the end of the session the participant will be able to:

• Apply practice guidelines in the treatment of AD among various patient and clinical scenarios, and describe their strengths and weaknesses
• Describe the goal of treatment and understand current therapies used for treatment for AD
• Describe present and emerging drug therapies for management of AD and apply them to patient cases taking into account the patient�s history.
• Describe present clinical controversies surrounding the clinical management of AD
• Describe clinical and logistical challenges associated with treating and educating patients with AD.

THIS COURSE HAS EXPIRED. NO CREDIT WILL BE ISSUED FOR COMPLETING IT.

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Dr. Peck Ong, MD, Associate Professor of Clinical Pediatrics, Division of Clinical Immunology and Allergy, Children’s Hospital Los Angeles; Department of Pediatrics, University of Southern California, Keck School of Medicine, Los Angeles, CA is a consultant for Pfizer.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Sanofi Aventis / Genzyme.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

*Required to view Printable PDF Version